

* Alexander Abitbol provides medical services through Dr. A. Abitbol Medicine Professional Corporation

CPU Toronto 1929 Bayview Avenue, Suite 125, Toronto, Ontario, M4G 3E8, Canada

Tel (416) 645-2929

Oakville 3075 Hospital Gate, Suite 301, Oakville, Ontario, L6M 1M1, Canada

Tel (905) 377-0040

CURRICULUM VITAE**Education, Certification & Licenses**

2020-2022	ICH-GCP Certificate	Syneos Health
2015	Certification in Endocrinology & Metabolism	American Board of Internal Medicine
2015	Certification in Endocrinology & Metabolism	Royal College of Physicians & Surgeons of Canada
2014	Internal Medicine	American Board of Internal Medicine
2014	Internal Medicine	Royal College of Physicians & Surgeons of Canada
2014	United States Medical Licensing Exam Step 3	National Board of Medical Examiners
2011	Licentiate	Medical Council of Canada
2006-2010	M.D.C.M.	McGill University Faculty of Medicine, Montréal QC
2005-2006	Pre-Med Year	McGill University Faculty of Science, Montréal QC
2003-2005	Diploma of Collegial studies in Health Sciences	Marianopolis College, Montréal QC

Professional Activities

2018-Present	Assistant Medical Director	LMC Diabetes & Endocrinology
2017-Present	Event Chair – Clinical Practice Update for Primary care	LMC Diabetes & Endocrinology
2017-Present	Principal Investigator	LMC Clinical Research Inc. d.b.a. Centricity Research
2015-Present	Sub-Investigator	LMC Clinical Research Inc. d.b.a. Centricity Research
2015-Present	Associate Endocrinologist	LMC Diabetes & Endocrinology
2015-2018	Internal Medicine Consultant	Talin Medical Centre, Candia QC
2014-2015	Internal Medicine Consultant	Montreal Metabolic Medical Centre, Montréal QC
2013-2015	Endocrinology & Metabolism Resident	McGill University Health Centre, Montréal QC
2010-2013	Internal Medicine Resident	McGill University Health Centre, Montréal QC
2010-2013	Physicianship Course Resident Teacher	McGill University Faculty of Medicine, Montréal QC

Clinical Research & Presentations*

2022	Chu L, Bhogal SK, Lin P, Steele A, Fuller M, Ciaccia A, et Abitbol A . AWAREness of diagnosis and treatment of Chronic Kidney Disease in adults with Type 2 Diabetes (AWARE-CKD in T2D). Can J Diabetes. 2022 Feb 3 [published online ahead of print]
2021	Chu L, Fuller M, Jervis K, Ciaccia A, Abitbol A . Prevalence of Chronic Kidney Disease in Type 2 Diabetes: The Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. Clin Ther. 2021 Sep;43(9):1558–73.
2021	Chu L, Fuller M, Jervis K, Bhogal SK, Abitbol A . 410-P: Therapeutic Profile from the Canadian REgistry of Chronic Kidney Disease in Diabetes Outcomes (CREDO) Study. [Meeting Abstract]
2021	Elliott T, Becca S, Beharry R, Tsoukas MA, Zarruk A, Abitbol A . The impact of flash glucose monitoring on glycated hemoglobin in type 2 diabetes managed with basal insulin in Canada: A retrospective real-world chart review study. Diab Vasc Dis Res. 2021 Jul-Aug;18(4):14791641211021374. doi: 10.1177/14791641211021374. PMID: 34275385; PMCID: PMC8481728
2021	Abitbol A , Siemens R, Nightingale N, Stewart J, Toutounji MJ, Goldenberg R. Persistence of GLP-1 RA in combination with basal insulin among adults with type 2 diabetes in Canada. Diabetes Res Clin Pract. 2021 Jul;177:108920. doi: 10.1016/j.diabres.2021.108920. Epub 2021 Jun 15. PMID: 34139288
2020	The Canadian LMC Diabetes Registry: A Profile of the Demographics, Management, and Outcomes of Individuals with Type 1 Diabetes Authors: R. Aronson, R. Brown, A. Abitbol , R. Goldenberg, Z. Yared, B. Ajala, JF. Yale – LMC Diabetes & Endocrinology
2016-2019	First Assessment of the Performance of an Implantable CGM System Through 180 Days in a Primarily Adolescent Population with Type I Diabetes Authors: R. Aronson, A. Abitbol , K.S. Tweden – LMC Diabetes & Endocrinology, Senseonics
2016-2018	Real-World Health Outcomes in Patients with T2D Initiating Insulin Glargine 300 U/mL vs. Insulin Glargine 100 U/mL in a Specialist Endocrinology Practice Authors: A. Abitbol , R. Brown, D. Jiandani, R. Aronson – LMC Diabetes & Endocrinology
2016-2017	Advanced Self-Care Program: Preliminary Results from a Six-Month Intervention for Patients with Chronically Uncontrolled Diabetes Authors: A. Abitbol , R. Brown, D. Jiandani, A. Walker, R. Aronson – LMC Diabetes & Endocrinology
2016-2017	Real-World Health Outcomes of Dapagliflozin vs. a DPP4-inhibitor or Sulfonylurea in Type 2 Diabetes Authors: R. Brown, A. Abitbol , R. Aronson – LMC Diabetes & Endocrinology
2016	Efficacy of Pharmacist Intervention in Patient Non-Adherence Authors: D. Aghili, M. Patel, N. Salib, J. Cho, T. Cheung, R. Aronson, A. Telner, A. Abitbol , H. Khandwala
2014-2018	Overnight Glucose Control with Dual- and Single-hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: Randomized Controlled Trial Authors: A. Abitbol , R. Rabasa-Lhoret, V. Messier, L. Legault, M. Smaoui, N. Cohen, A. Haidar – IRCM Juvenile Diabetes Research Foundation Innovative Grant, J-A DeSève Research Chair Grant

Professional Memberships

2015-Present	Fellow of the Royal College of Physicians of Canada, College of Physicians & Surgeons of Ontario, Ontario Medical Association, Diplomate of the Nation Board of Medical Examiners
2014-Present	Diplomate of the American Board of Internal Medicine
2013-Present	Canadian Society of Endocrinology & Metabolism, American Association of Clinical Endocrinologists
2010-Present	Collège des Médecins du Québec

Clinical Trials & Research Activities

2015-2022	H9X-MC-GBDJ (Eli Lilly), APD35-G000-401 (Eisai), B1481022 (Pfizer), B1481038 (Pfizer), B1481045 (Pfizer), 200977 (GSK), MK8835-002 (Merck), D1693C00001 (AstraZeneca), D1690C00024 (AstraZeneca), LPS14347 (Sanofi), MK-0431-845 (Merck), D5881C00004 (AstraZeneca), APD356-G000-401 (Eisai), GOAL-RCT (LMC Diabetes & Endocrinology), LX4211.312 (Lexicon), DRI13940 (Sanofi), CTP-0024 (Senseonics), GS-US-401-1852 (Gilead), C1171002 (Pfizer), EFC14834 (Sanofi), I8H-MC-BDCB (Eli Lilly), BD-SWATCH-015 (BD), 2 (FNIH), FIT (LMC Diabetes & Endocrinology), ZP4207-16136 (Zealand), NN1250-4252 (Novo Nordisk), K-877-302 (KOWA), MSC15146 (Sanofi), EFC14837 (Sanofi), XSGP-303 (Xeris), EFC14828 (Sanofi), I8H-MC-BDCB (Eli Lilly), I8B-MC-ITSA (Eli Lilly), ZP4207-16137 (Zealand), T1Dexi (JAEB), FIT Untethered (LMC Diabetes & Endocrinology), EFC14868 (Sanofi), EFC14828 (Sanofi), LPS15544 (Sanofi), XSGP-304 (Xeris), XSMP-204 (Xeris), NN1250-4419 (Novo Nordisk), NN9535-4352 (Novo Nordisk), REMIT iDegLira (PHRI), EX9924-4473 (Novo Nordisk), I8B-MC-ITRO (Eli Lilly), D5676C00001 (AstraZeneca), AT-001-2001 (Applied Therapeutics), I8F-MC-GPGN (Eli Lilly), C2541013 (Pfizer), ZT-01-1001 (Zucara), WVE-HDSNP1-001 (Wave), WVE-HDSNP2-001 (Wave), 254PD101 (Biogen), VBI-2902a-CT01 (VBI), NN9931-4553 (Novo Nordisk), NN9924-4635 (Novo Nordisk), NN1436-4625 (Novo Nordisk), CP-PRO-CoVLP-021 (Medicago), NN1436-4479 (Novo Nordisk), NN1436-4481 (Novo Nordisk), D9183C00001 (AstraZeneca), IMMEDIATE (LMC), ANJ900D3501 (Anji), VAC18193RSV3001 (Janssen), AXA1125-101 (Axcella), ZT01-CL-1003 (Zucara), C3671013 (Pfizer), I8B-MC-ITSU (Lilly), AROAPOC3-2001 (Arrowhead), PRO-CL-002 (Providence), etc.
-----------	--

* >10 presentations